OncoMatch

OncoMatch/Clinical Trials/NCT05438368

GD2/CD70 Bi-specific CAR-T Cell Therapy

Is NCT05438368 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies bi-4SCAR GD2/CD70 T cells for cancer disease.

Phase 1/2RecruitingShenzhen Geno-Immune Medical InstituteNCT05438368Data as of May 2026

Treatment: bi-4SCAR GD2/CD70 T cellsThe purpose of this study is to assess the feasibility, safety and efficacy of GD2/CD70 bi-specific CAR-T cell therapy in patients with GD2 and/or CD70 positive tumor. Another goal of the study is to learn more about the function of the GD2/CD70 bi-specific CAR-T cells and their persistency in patients.

Check if I qualify

Extracted eligibility criteria

Biomarker criteria

Required: GD2 overexpression (positive expression by immunohistochemistry or flow cytometry)

The expression status of GD2 or CD70 antigens in the tumor tissue will be determined for eligibility. Positive expression is defined by GD2 and PMSA antibody staining results based on immunohistochemistry or flow cytometry analyses.

Required: CD70 overexpression (positive expression by immunohistochemistry or flow cytometry)

The expression status of GD2 or CD70 antigens in the tumor tissue will be determined for eligibility. Positive expression is defined by GD2 and PMSA antibody staining results based on immunohistochemistry or flow cytometry analyses.

Prior therapy

Min 1 prior line

Must have received: standard first-line therapy

Patients with tumors received standard first-line therapy

Cannot have received: genetically engineered GD2 or CD70-specific CAR T cells

Previous treatment with other genetically engineered GD2 or CD70-specific CAR T cells.

Lab requirements

Blood counts

white blood cell count ≥1000/ul, absolute neutrophil count ≥500/ul, absolute lymphocyte count ≥500/ul, platelet count ≥25,000/ul (not achieved by transfusion)

Kidney function

serum creatinine less than 3 times upper limit of normal

Liver function

alt <3x uln, ast <3x uln; serum bilirubin and alkaline phosphatase <2x uln

Cardiac function

left ventricular ejection fraction greater than or equal to 40/55 percent

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify